Key Product Details

Species Reactivity

SARS-CoV-2, Virus

Applications

Validated:

Simple Western, Western Blot

Cited:

IF/IHC, Simple Western

Label

Unconjugated

Antibody Source

Polyclonal Rabbit

Format

BSA Free

Concentration

1.0 mg/ml

View all SARS-CoV-2 Nucleocapsid Antibodies »

Product Specifications

Immunogen

Full length recombinant SARS-CoV-2 nucleocapsid protein.

Clonality

Polyclonal

Host

Rabbit

Scientific Data Images for SARS-CoV-2 Nucleocapsid Antibody - BSA Free

Western Blot: SARS-CoV-2 Nucleocapsid AntibodyBSA Free [NBP3-00510]

Western Blot: SARS-CoV-2 Nucleocapsid AntibodyBSA Free [NBP3-00510]

Western Blot: SARS-CoV-2 Nucleocapsid Antibody [NBP3-00510] - Western blot shows recombinant SARS-CoV-2 Nucleocapsid protein. PVDF membrane was probed with 2 ug/mL of Rabbit Anti-SARS-CoV-2 Nucleocapsid Polyclonal Antibody (Catalog # NBP3-00510) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (HAF008). A specific band was detected for SARS-CoV-2 Nucleocapsid at approximately 55 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.
Simple Western: SARS-CoV-2 Nucleocapsid AntibodyBSA Free [NBP3-00510]

Simple Western: SARS-CoV-2 Nucleocapsid AntibodyBSA Free [NBP3-00510]

Simple Western: SARS-CoV-2 Nucleocapsid Antibody [NBP3-00510] - Simple Western lane view shows recombinant SARS-CoV-2 Spike S1 RBD (receptor binding domain) protein (negative sample), recombinant SARS-CoV-2 Spike S1 subunit protein (negative sample), recombinant SARS-CoV-2 Spike S1/S2 subunit protein (negative sample), and recombinant SARS-CoV-2 Nucleocapsid protein, loaded at 0.2 mg/mL. Specific bands were detected for SARS-CoV-2 Nucleocapsid at approximately 60 kDa (as indicated) using 20 ug/mL of Rabbit Anti-SARS-CoV-2 Nucleocapsid Polyclonal Antibody (Catalog # NBP3-00510). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Applications for SARS-CoV-2 Nucleocapsid Antibody - BSA Free

Application
Recommended Usage

Simple Western

20 ug/mL

Western Blot

2 ug/mL

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

Background: SARS-CoV-2 Nucleocapsid

The SARS-CoV-2 Nucleocapsid protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The nucleocapsid protein is an RNA-binding protein that is essential for viral assembly into a ribonucleoprotein complex and also functions in viral budding (2,3). More specifically, after viral replication and RNA synthesis, the viral genomes that are encapsulated by the nucleocapsid protein will bud into the membrane and help with mature virus formation (2). The nucleocapsid protein is synthesized as 419 amino acids (aa) in length with a theoretical molecular weight of 45.6 kDa (4). Structurally, the nucleocapsid protein contains an RNA-binding domain (N1b), a dimerization domain (N2b), and a few shorter regions (N1a, N2a, and spacer B/N3) (3). It is the N1b domain that is suggested to be involved in RNA binding (3). The nucleocapsid N1b domain contains a beta-hairpin, a loop region, and a beta-sheet core, giving it a right-handed shape (3). Conversely, the N2b domain functions in dimerization which promotes assembly into a helical filament where the dimer interface is made of two beta-strands and an alpha-helix portion (3). Inhibition of nucleocapsid assembly may be a potential target for treating COVID-19 infection.

Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003

4. Uniprot (P0DTC9)

5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949

Alternate Names

2019-nCoV N Protein, 2019-nCoV Nucleocapsid Protein, COVID-19 N protein, COVID-19 nucleocapsid protein, Human coronavirus Nucleoprotein, nucleocapsid phosphoprotein, Nucleocapsid protein, Nucleoprotein, ORF9; structural protein, SARS-CoV-2, SARS-CoV-2 Nucleocapsid protein, SARS-CoV-2 N protein, SARSCoV2 Nucleoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein

Gene Symbol

N

Additional SARS-CoV-2 Nucleocapsid Products

Product Documents for SARS-CoV-2 Nucleocapsid Antibody - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 Nucleocapsid Antibody - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.